Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis.
This article represents the proceedings of a symposium at the 2000 ISBRA Meeting in Yokohama, Japan. The presentation was Nonalcoholic fatty liver disease: Implications for alcoholic liver disease pathogenesis, by Anna Mae Diehl.
Diehl
A M
AM
Department of Medicine, The Johns Hopkins University, Baltimore, Maryland 21205, USA. amdiehl@welch.jhu.edu
D000818:Animals; D017209:Apoptosis; D004731:Endotoxins / Q000009:adverse effects; D005234:Fatty Liver / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006801:Humans; D020738:Leptin / Q000172:deficiency* / Q000276:immunology; D008099:Liver / Q000276:immunology / Q000473:pathology*; D008108:Liver Diseases, Alcoholic / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D051379:Mice; D008820:Mice, Obese; D008930:Mitochondria, Liver / Q000276:immunology / Q000378:metabolism*; D009336:Necrosis; D009765:Obesity / Q000276:immunology / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
D004731:Endotoxins; D020738:Leptin; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha